A Study of TQB3454 Tablets in Patients With Blood Tumors

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

RECRUITING

Clinical Phase

PHASE1/PHASE2

Total Enrollment

80 participants

Study Classification

INTERVENTIONAL

Study Start Date

2023-07-10

Study Completion Date

2025-12-31

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

The purpose of this clinical trial is to evaluate the safety of TQB3454 tablets in patients with acute myeloid leukemia and myelodysplastic syndrome, and determine the phase II recommended dose.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

A Clinical Trial of TQB3455 Tablets in Patients With Hematological Malignancies

NCT06550713

Acute Myeloid Leukemia (AML) Myelodysplastic Syndrome (MDS)

RECRUITING PHASE1

Clinical Study of TQB2618 Injection in Combination With Demethylation Drugs in Patients With Recurrent/Refractory Acute Myeloid Leukemia, Myelodysplastic Syndromes

NCT05426798

Recurrent/Refractory Acute Myeloid Leukemia, Myelodysplastic Syndromes

UNKNOWN PHASE1

A Clinical Trial on the Safety and Efficacy of TQB3909 Tablets in Patients With Recurrent or Refractory Chronic Lymphocytic Leukemia (CLL) /Small Lymphocytic Lymphoma (SLL) .

NCT05959694

Chronic Lymphocytic Leukemia Small Lymphocytic Lymphoma

RECRUITING PHASE1/PHASE2

A Clinical Trial to Evaluate the Safety and Tolerability of TQB3911 Tablets in Patients With BCR::ABL Fusion Gene Positive Leukemia

NCT06672263

Chronic Myelogenous Leukemia

NOT_YET_RECRUITING PHASE1

A Clinical Trial of TQB3909 Tablets in Combination With Azacitidine for the Treatment of Myeloid Malignancies

NCT07011186

Myeloid Malignancy

RECRUITING PHASE1/PHASE2

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Acute Myeloid Leukemia Myelodysplastic Syndromes

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

NA

Intervention Model

SINGLE_GROUP

Primary Study Purpose

TREATMENT

Blinding Strategy

NONE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

TQB3454 Tablets

TQB3454 Tablets, orally administered, 28 days as a treatment cycle.

Group Type EXPERIMENTAL

TQB3454 Tablets

Intervention Type DRUG

TQB3454 Tablets is a selective isocitrate dehydrogenase 1 (IDH1) mutation inhibitor

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

TQB3454 Tablets

TQB3454 Tablets is a selective isocitrate dehydrogenase 1 (IDH1) mutation inhibitor

Intervention Type DRUG

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Patients voluntarily joined the study and signed informed consent with good compliance.
* Men and women; The expected survival is ≥3 months.
* Negative serum/urine pregnancy test within 7 days prior to initial dose and must be non-lactating; Women of childbearing age agree to use contraception (such as an intrauterine device, birth control pill or condom) during the study and for six months after the study completion; Men agreed to use contraception during the study period and for six months after the end of the study.
* The major organs are functioning well;
* For Relapsing/refractory acute myeloid leukemia (AML):

1. According to the classification criteria for Hematopoietic and lymphoid tissue tumors revised by the World Health Organization (WHO) in 2016, AML confirmed by bone marrow cell morphology, excluding acute promyelocytic leukemia (APL).
2. ≥18 years old; Eastern Cooperative Oncology Group (ECOG) score is 0\~2.
3. Blood biochemical examination:

i: Total bilirubin (TBIL) ≤1.5× upper limit of normal value (ULN), liver infiltration ≤3×ULN in Gilbert syndrome patients or tumor diseases; ii: Alanine aminotransferase (ALT) and aspartate aminotransferase (AST) ≤2.5×ULN; ALT and AST≤5×ULN if liver infiltration was associated.
* For myelodysplastic syndrome (MDS) with higher risk:

1. MDS patients were confirmed by bone marrow cell morphology and cytogenetics and met the classification criteria of hematopoietic and lymphoid tissue tumors revised by WHO in 2016.
2. ≥18 years old; ECOG score is 0\~2. c. Blood biochemical examination:

i: Total bilirubin (TBIL) ≤1.5× upper limit of normal value (ULN), liver infiltration ≤3×ULN in Gilbert syndrome patients or tumor diseases.

ii: Alanine aminotransferase (ALT) and aspartate aminotransferase (AST) ≤2.5×ULN; ALT and AST≤5×ULN if concomitant with liver infiltration.

Exclusion Criteria

* Tumor diseases and history:

1. The tumor has or is suspected to involve the central nervous system, or primary Central nervous system leukemia.
2. Present or present with other malignant tumors within 3 years prior to the first dose. Except the following conditions: for other malignancies treated with a single operation, achieving a 5-year continuous disease-free survival (DFS); Cured cervical carcinoma in situ, non-melanoma skin cancer, and superficial bladder tumors \[Ta (non-invasive tumor), Tis (carcinoma in situ), and T1 (tumor infiltrating basal membrane)\].
3. Severe life-threatening complications of leukemia, such as uncontrolled bleeding, hypoxia or shock pneumonia, and disseminated intravascular coagulation.
* Previous antitumor therapy:

1. Received National Medical Products Administration (NMPA) approved Chinese patent drugs with anticancer indications specified in the drug label within 2 weeks prior to initial administration.
2. Toxicities associated with previous antineoplastic therapy did not return to CTCAE≤1, except for hair loss, fatigue and poor appetite.

3\. Associated diseases and history:



1. Abnormal liver.
2. Renal abnormalities.
3. Gastrointestinal abnormalities.
4. Cardio-cerebrovascular abnormalities.
5. Immune-related history.
6. Lung disease.
7. Comorbidities that were severe or poorly controlled and, in the investigator's judgment, significantly compromised patient safety or hindered study completion.
8. Risk of bleeding.
* History of drug abuse or drug abuse.
* Participated in clinical trials of other drugs within the past 30 days;
* It is estimated that the patient's compliance to participate in this clinical study is insufficient.

Minimum Eligible Age

18 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No